主题 : 3.0alpha1编译android时：ERROR: The device does not support the application's targetted CPU ABIs!
级别: 新手上路
可可豆: 42 CB
威望: 49 点
在线时间: 10(时)
发自: Web Page
3.0alpha1编译android时：ERROR: The device does not support the application's targetted CPU ABIs!&&&
LiuJing@LiuJing-Notepad /cygdrive/d/cocos2d-x-3.0alpha1/samples/Cpp/HelloCpp/proj.android
$ ./ndkgdb.sh
NDK_ROOT = /cygdrive/d/android-ndk-r9c
SDK_ROOT = /cygdrive/d/sdk
COCOS2DX_ROOT = /cygdrive/d/cocos2d-x-3.0alpha1/samples/Cpp/HelloCpp/proj.android/../../../..
APP_ROOT = /cygdrive/d/cocos2d-x-3.0alpha1/samples/Cpp/HelloCpp/proj.android/..
APP_ANDROID_ROOT = /cygdrive/d/cocos2d-x-3.0alpha1/samples/Cpp/HelloCpp/proj.android
APP_ANDROID_NAME = org.cocos2dx.hellocpp
Killing and restarting org.cocos2dx.hellocpp
++ /cygdrive/d/sdk/platform-tools/adb shell am force-stop org.cocos2dx.hellocpp
++ NDK_MODULE_PATH=/cygdrive/d/cocos2d-x-3.0alpha1/samples/Cpp/HelloCpp/proj.android/../../../..:/cygdrive/d/cocos2d-x-3.0alpha1/samples/Cpp/HelloCpp/proj.android/../../../../cocos2dx/platform/third_party/android/prebuilt
++ /cygdrive/d/android-ndk-r9c/ndk-gdb --adb=/cygdrive/d/sdk/platform-tools/adb --verbose --start --force
Android NDK installation path: /cygdrive/d/android-ndk-r9c
Using specific adb command: /cygdrive/d/sdk/platform-tools/adb
ADB version found: Android Debug Bridge version 1.0.31
Using ADB flags:
Using JDB command: /cygdrive/c/Program Files/Java/jdk1.6.0_43/bin/jdb
Using auto-detected project path: .
Found package name: org.cocos2dx.hellocpp
jni/Android.mk:19: *** Android NDK: Aborting.    .  Stop.
ABIs targetted by application: Android NDK:
Device API Level: 15
Device CPU ABIs: armeabi-v7a armeabi
ERROR: The device does not support the application's targetted CPU ABIs!
       Device supports:  armeabi-v7a armeabi
       Package supports: Android NDK:
运行环境：64win7,jdk6,cocos2d-x 3.0 pre1,ndk8编译的是原生3.0 pre1的helloCpp。按照谷歌提示的一下几个方法皆尝试过1、将hellocpp的ndkgdb的修改为NDK_MODULE_PATH=&${COCOS2DX_ROOT}&:&${COCOS2DX_ROOT}&/external 参考：（请各位注意，该文件下的NDK_MODULE_PATH所指路径依然是2.0和3.0pre0的路径结构&${COCOS2DX_ROOT}&/cocos2dx/platform/third_party/android/prebuilt）2、修改hellpCpp\jni\application.mk文件，将APP_ABI := armeabi-v7aAPP_OPTIM := debug 或APP_ABI := armeabi-v7a armeabi追加至文件末尾3、换电脑，重新下载并配置所有环境4、换手机，小米1，小米2，G14，中兴u988s
级别: 新手上路
可可豆: 42 CB
威望: 49 点
在线时间: 10(时)
发自: Web Page
Re:3.0alpha1编译android时：ERROR: The device does not support the application's targetted CP ..
是不是3.0pre1本身的问题？
级别: 侠客
UID: 265187
可可豆: 251 CB
威望: 250 点
在线时间: 32(时)
发自: Web Page
Re:3.0alpha1编译android时：ERROR: The device does not support the application's targetted CP ..
做一个demo放到github上，然后发链接上来引用 引用楼主liujing906qd于 11:21发表的 3.0alpha1编译android时：ERROR: The device does not support the application's targetted CPU ABIs! :&pre class=&brush: toolbar: auto-links:&&LiuJing@LiuJing-Notepad /cygdrive/d/cocos2d-x-3.0alpha1/samples/Cpp/HelloCpp/proj.android$ ./ndkgdb.shNDK_ROOT = /cygdrive/d/android-ndk-r9c.......
级别: 新手上路
可可豆: 67 CB
威望: 67 点
在线时间: 49(时)
发自: Web Page
Re:3.0alpha1编译android时：ERROR: The device does not support the application's targetted CP ..
楼主解决了吗
关注本帖(如果有新回复会站内信通知您)
发帖、回帖都会得到可观的积分奖励。
按"Ctrl+Enter"直接提交
关注CocoaChina
关注微信 每日推荐
扫一扫 关注CVP公众号
扫一扫 浏览移动版you video card does not support alpha blending with floating point render targets_百度知道
you video card does not support alpha blending with floating point render targets
想玩英雄无敌7，结果显示上面的英文求大神帮助
我有更好的答案
这游戏可能和你的显卡不兼容，在下载游戏的网页上看看这个游戏的配置，是不是与你的电脑不适合……
采纳率：64%
为您推荐：
其他类似问题
换一换
回答问题，赢新手礼包
个人、企业类
违法有害信息,请在下方选择后提交
色情、暴力
我们会通过消息、邮箱等方式尽快将举报结果通知您。当前位置： &
求翻译：Your video card does not support alpha blening with floating point rendenr targets (D3DFMT_A16B16G16R16F),which is required to run this game.exiting...是什么意思？
Your video card does not support alpha blening with floating point rendenr targets (D3DFMT_A16B16G16R16F),which is required to run this game.exiting...
问题补充：
你的显卡不支持Alpha blening浮点rendenr目标（ D3DFMT_A16B16G16R16F ） ，运行这个game.exiting这是需要...
您的显示卡不支持blening与浮动小数点rendenr目标(D3DFMT_A16B16G16R16F)的阿尔法，要求跑这个game.exiting…
您的显示卡不支持blening与浮动小数点rendenr目标D3DFMT_A16B16G16R16F的 (阿尔法)，要求跑这game.exiting…
您的视频卡不支持 alpha blening 与浮动点 rendenr 目标 （D3DFMT_A16B16G16R16F），其中运行此 game.exiting 所需......
你的视频卡以浮点不支持 blening 的 alpha rendenr 目标 ( D3DFMT_A16B16G16R16F )，被要求变成这么 game.exiting ...
我来回答：
参考资料：
* 验证码：
登录后回答可以获得积分奖励，并可以查看和管理所有的回答。 |
我要翻译和提问
请输入您需要翻译的文本！Your video card dose not support alpha blending with ...【使命召唤吧】_百度贴吧
&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&签到排名：今日本吧第个签到，本吧因你更精彩，明天继续来努力！
本吧签到人数：0可签7级以上的吧50个
本月漏签0次！成为超级会员，赠送8张补签卡连续签到：天&&累计签到：天超级会员单次开通12个月以上，赠送连续签到卡3张
关注：638,346贴子：
Your video card dose not support alpha blending with ...
Your video card dose not support alpha blending with floating point render targets(D3DFMT_A16B16G16R16F), whith is required to run this game.Exiting...
赶紧给我写个配置快快的快快的我有钱有钱
第一次在使吧看见英文帖子标题我以为国际友人来了！
贴吧热议榜
使用签名档&&
保存至快速回贴Please fill in this field
Password *
Please fill in this field
Remember me
Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage
1, 2,3, 3,4, 1, 3 and 1*
1Department of Integrative Neurophysiology, Center for Neurogenomics and Cognitive Research, VU University Amsterdam, Amsterdam, Netherlands
2Department of Clinical Neurophysiology and MEG, VU University Medical Center, Amsterdam, Netherlands
3Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, Netherlands
4Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands
Alzheimer's disease (AD) is a devastating disorder of increasing prevalence in modern society. Mild cognitive impairment (MCI) is considered a transitional stage between normal aging and AD; however, not all subjects with MCI progress to AD. Prediction of conversion to AD at an early stage would enable an earlier, and potentially more effective, treatment of AD. Electroencephalography (EEG) biomarkers would provide a non-invasive and relatively cheap screening tool to predict conversion to AD; however, traditional EEG biomarkers have not been considered accurate enough to be useful in clinical practice. Here, we aim to combine the information from multiple EEG biomarkers into a diagnostic classification index in order to improve the accuracy of predicting conversion from MCI to AD within a 2-year period. We followed 86 patients initially diagnosed with MCI for 2 years during which 25 patients converted to AD. We show that multiple EEG biomarkers mainly related to activity in the beta-frequency range (13–30 Hz) can predict conversion from MCI to AD. Importantly, by integrating six EEG biomarkers into a diagnostic index using logistic regression the prediction improved compared with the classification using the individual biomarkers, with a sensitivity of 88% and specificity of 82%, compared with a sensitivity of 64% and specificity of 62% of the best individual biomarker in this index. In order to identify this diagnostic index we developed a data mining approach implemented in the Neurophysiological Biomarker Toolbox (). We suggest that this approach can be used to identify optimal combinations of biomarkers (integrative biomarkers) also in other modalities. Potentially, these integrative biomarkers could be more sensitive to disease progression and response to therapeutic intervention.
Introduction
Caused by an increasing average age of the population in the developed world, dementia is becoming a major healthcare problem. Alzheimer's disease is the most common form of dementia and the golden standard for diagnosis is the post-mortem identification of Amyloid Beta 42 depositions and tangles (; ). It has been suggested that Alzheimer's disease begins years, maybe even decades before actual cognitive symptoms appear (). However, normal ageing is also characterized by a slow decline of cognitive functions, which means it can be difficult to disentangle normal ageing from Alzheimer at a very early stage.
Patients with mild cognitive impairment (MCI) are at high risk of developing Alzheimer's disease. The label MCI is given when there is a cognitive complaint (mostly memory), which can also be demonstrated on formal testing, while general cognitive functioning is relatively intact and a patient is still living independently (; ; ). Therapies that stop the conversion to Alzheimer's disease unfortunately remain to be developed, but it is likely that these drugs or therapies will appear in the future (; ). It is plausible that these therapies will be most effective before major brain damage has occurred and it is, therefore, important to develop biomarkers sensitive of this very early stage (). Early-stage identification may also help the development of new treatments that are more effective at this stage as it can facilitate monitoring of the response to the intervention.
We here focus on biomarkers obtained from electroencephalography (EEG) recordings in the eyes-closed resting state (ECR). EEG biomarkers are optimal for screening purposes because the EEG recording can be obtained using relative cheap and non-invasive equipment, which is widely available and fast to use. Several previous EEG studies of conversion from mild cognitive impairment to Alzheimer's disease have been conducted (, ; ; ; ; ; , ; ; , ; ; ,, , ; ) mainly using biomarkers such as spectral measures and synchronization between brain regions. Machine-learning techniques have been used to explore differences between MCI and AD with varying success (; ; ; ; ; ; ), however, only few studies have tried to predict the conversion from MCI to AD (; ; ). Many studies typically focus on a small number of biomarkers (on the order of 15 marker values), and some do not have adequate validation of their results on independent groups. We perform large-scale data mining of multiple biomarkers (Figure ) and validate our results on an independent group of subjects.
Figure 1. An integrative approach toward improved prediction of mild cognitive impairment to Alzheimer's disease conversion. (A) Diagram of processing flow. We calculate biomarkers on the second year EEG hereafter we mapped all potential differences between MCI and AD using Student's t-test (Difference map). Next, we performed logistic regression on each single biomarker. Biomarkers with best single-classification power were seeded to a gene this algorithm further optimized the combined biomarker set. This biomarker set was then used to predict MCI to AD conversion based on the first-year EEG recording. To evaluate the lower bound on the classification, half-split cross-validation was performed. Finally, the outcome performance was evaluated on the 1st EEG recording. (B) Overview of how the MCI patient cohort splits into AD, another diagnosis, or remain MCI one or 2 years after the in-take. (C) The integration of multiple biomarkers can reveal hidden separation boundaries. Here, we show two simulated biomarkers where the red and blue groups are overlapping if we only consider the single biomarkers. By combining the biomarkers, we see a clear separation boundary at the diagonal. Classification algorithms aim to identify this boundary, and use it to predict group association for new data.
Our focus is on the EEG measured as part of the initial hospital intake test, combined with longitudinal recordings measured 1 year after the initial intake test. We have mapped several classical EEG biomarkers, such as frequency and power, but also non-classical biomarkers such as detrended fluctuation analysis and oscillation burst analysis (; ). By combining several biomarkers, it is often possible to find better separation boundaries between two groups (Figure ), because each biomarker gives additional information (). In this longitudinal study we show that EEG biomarkers from the initial hospital in-take test retrospectively can be used in a classifier algorithm to predict the diagnosis that the patient obtained within the subsequent 2 years.
Methods and Materials
The study involved 86 mild cognitive impairment (MCI) subjects who were referred to the Alzheimer Center at the VU University Medical Center in Amsterdam, the Netherlands (Figure ). Upon the first visit at the Alzheimer Center, all subjects underwent a thorough 1-day examination consisting of history taking, physical, and neurological assessment, neuropsychological testing including the Mini Mental State Examination (MMSE) (), laboratory tests, structural magnetic resonance imaging (MRI), and a routine electroencephalogram (EEG). After reviewing the clinical and ancillary imaging data, a multidisciplinary team established a consensus-based final diagnosis for each patient. The initial diagnosis of MCI was based on the criteria set by (), consisting of (a) objective memory impairment as seen during neuropsychological evaluation, defined by performances &#x0 standard deviation below the mean value of education—and that of age matched controls, (b) normal activities of daily living, and (c) a rating score of 0.5 in clinical dementia ().
All MCI subjects were followed up clinically during an average period of 709 ± [537:779] days (1.9 years) (median ± 95% confidence interval). The clinical follow up included medical history and functional status assessment re-examination in order to measure potential changes in the cognitive domain. MCI subjects who showed steady or enhanced cognitive functioning (but still fulfilled the criteria for MCI) during re-assessment were considered as MCI-stable, while MCI subjects who showed impoverished cognitive functioning, and fulfilled the NINDS-ADRDA criteria () to be diagnosed with Alzheimer's disease, were considered to belong to the AD-converter group. Exclusion criteria were previous head trauma, history of neurological or psychiatric disease or use of psychotropic medications. Patients progressing from MCI to other disorders than Alzheimer's disease (n = 22) were excluded from the analyses reported here. These pa “Subjective complaints” (n = 9), possible Alzheimer's disease (n = 1), frontal lobe dementia (n = 1), vascular dementia (n = 3), Lewy body dementia (n = 1), dementia other (n = 2), psychiatric (n = 2), or another neurological disorder (n = 3). The measurements were approved by the Ethics Committee of the VU University Medical Center, and were in accordance to the Helsinki declaration. All subjects signed an informed consent.
EEG Recordings
Twenty-one channel EEGs were recorded in a sound attenuated, electrically shielded, and dimly lit room. These recordings were performed with OSG digital equipment (Brainlab®) at the following locations of the international 10–20 system: Fp2, Fp1, FT9, FT10, F8, F7, F4, F3, A2, A1, T4, T3, C4, C3, T6, T5, P4, P3, O2, O1, Fz, Cz, and Pz. The recording was referenced to the common average of all electrodes, excluding Fp1 and Fp2. Sampling frequency was 500 Hz and analogue-digital precision was 16 bit. The impedance of all electrodes was less than 5 kΩ. Recordings were made with a 70 Hz low-pass filter (time constant 1 s). Subjects sat in a reclined chair for approximately 20 min. During this period the subjects kept their eyes closed most of the time, however, at irregular intervals, they were asked to open their eyes when drowsiness was noticed. Approximately 15 min into the recording a memory task, which consisted of remembering pictogram images for 1 min was performed.
EEG Cleaning
The recordings during task and eyes-open were not analyzed. The EEG was viewed in windows of 5 s, and sharp transient artifacts were cut out. On average 17.8 [range (12.4:24.1)] minutes of eyes-closed rest EEG was left. The JADE ICA algorithm was then used to separate the signal into 23 components (). Eye movements, eye blinks, muscle artifacts, and heartbeat components were rejected, based on abnormal topography, component activation, activity distribution, and spectrum.
Biomarkers and Processing Flow
The Neurophysiological Biomarker Toolbox (NBT) () was used to organize, analyse, and calculate all biomarkers in this study (). An EEG biomarker is a quantitative measure derived from the EEG, e.g., the dominant frequency of the beta frequency band (13–30 Hz), to be used as a diagnostic or prognostic predictor of disease (Figure ).
Figure 2. An EEG biomarker is a quantitative measure derived from the EEG. For example the Beta peak frequency. (A) Time-frequency (TF-plot) plot of 6 s of an eyes-closed rest EEG signal (from Pz) (Wavelet). The color shows the power. Low-amplitude bursts in the beta-frequency band (13–30 Hz) not directly coupled with the strong alpha are observed. (B) The raw EEG signal used to calculate the TF-plot in (A). Clear and strong alpha (8–13 Hz) oscillations are observed. (C) Zooming in, we observe small peaks in the space between the strong alpha oscillation peaks, which correspond to the beta oscillations. (D) The power spectrum of the full-length EEG signal reveals a beta peak (left). To find the beta peak we first fit a 1/f baseline (right), next we fit a Gaussian to the small beta peak. We now
Beta peak frequency, Beta peak width, Beta peak corrected power (i.e., minus 1/f baseline), and peak uncorrected power.
We extracted 177 biomarkers from each EEG trace. We decided to focus on biomarkers we have had good experiences with in other studies, and acknowledge that many more biomarkers could have been selected.
Based on the broadband signal, we computed 28 biomarkers, namely: Hjorth's activity, mobility and complexity parameters (); Time domain Parameters (), Wackermann's global field strength, global frequency, and spatial complexity (), Barlow's amplitude, frequency and spectral purity (). Alpha peak frequency, peak width, power corrected for 1/f baseline (), when applicable the same parameters where found for double alpha peaks. Alpha-theta transition point (), Beta peak frequency (Figure ), width, power corrected for 1/f baseline (), same for second
Frequency stability was evaluated using different methods, by the standard deviation and interquartile range of the central frequency and maximum wavelet frequency calculated in windows, and by, the distribution parameters of the phase values above zero, and of the number of oscillation cycle peaks per window.
For each of the classical frequency bands—delta (1–3 Hz), theta (4–7 Hz), alpha (8–13 Hz), beta (13–30 Hz), and gamma (30–45 Hz)—we computed 13 namely: The amplitude envelope was extracted using Hilbert transform and characterized extensively. We calculated the spearman correlations of amplitude envelopes in different channels. The distribution of amplitude values was characterized by kurtosis, skewness, interquartile range, median, range, and variance. Furthermore, detrended fluctuation analysis characterizing long-range temporal correlations (; ; ), multifractality spectral width (; ) and oscillation bursts 95th percentile durations and sizes (; ) were calculated on the amplitude envelope. The instantaneous phase was also extracted using Hilbert transform, and the 95th percentile duration and size of the stable phase bursts (a phase bursts is defined as the period between phase slips) were calculated. In addition, we computed for all frequency bands and individualized frequency bands, defined as Alpha1 (APF = individually defined Alpha peak frequency): (APF–4 to APF–2) Hz, Alpha2: (APF–2 to APF) Hz, Alpha3: (APF to APF+2) Hz; Beta: (APF+2 to 30) Hz (), 7 biomarkers: absolute, relative power, and power ratios, furthermore, the central frequency, power in central frequency, bandwidth and spectral edge (; ). In total, we extracted 177 biomarker values from each EEG trace (Table ).
Table 1. Thirty-five biomarkers from different signal processing domains were extracted.
Next, we performed data mining on these biomarkers based on the second EEG recording (Figure ), to identify biomarkers that reached a significance level of p < 0.05 (student's t-test) for the comparison of stable MCI vs. AD-converters (based on the diagnosis after 2 years). We here use student's t-test because this test has best statistical power in most cases under the assumption of normal distributed biomarker values. The biomarkers were tested per channel, and a binomial multiple-comparison correction was performed (). The binomial multiple-comparison correction tests whether a significant number of channels are found (i.e., 3 or more channels, p < 0.05). The performance of two different classification algorithms (see below for details) in integrating significant biomarkers into a diagnostic index was then tested using their median values across significant channels.
Development of a Diagnostics Index
To move beyond single-biomarker classification we aimed to integrate several EEG biomarkers in a diagnostic index that would classify the AD-converter group from the MCI-stable group better than each individual biomarker. Using one dataset for development and testing is not recommended, because it is theoretically possible to find a perfect separation of two groups if enough biomarkers are included (so-called over-fitting). To counteract this issue we build our classification model based on the second EEG recording (which was obtained in 34 out of a total of 64 subjects that were either MCI-stable or AD-converters), and tested the classification accuracy retrospectively on the first EEG recording. Thirty subjects were not included in the training (22 MCI-stable, 8 AD-converters), because these subjects did not have any second-year recording. These subjects serve as our ultimate classification test. We also used half-split cross-validation to evaluate the stability and lower bound of the solution (see below).
Statistics: Logistic Regression with Genetic Search
Binary classification was performed using logistic regression. In logistics regression the binary outcome either AD-converter (1) or MCI-stable (0) is regressed with a linear combination of biomarkers. More specifically we fit a function f(z) using maximum likelihood.
f(z)=11+e−z
z=β0+∑i=1kβixi,(1)
and x are the k biomarkers included in the regression (included as medians across significant channels), and βi are the regression coefficients. The function f represents the probability of Alzheimer's disease. We use the 50% probability as our classification threshold, i.e., if f &#x0, the patient belong to the AD-converter group, otherwise the patient belongs to the MCI-stable group. We used a genetic search method to identify biomarkers that combined (using logistic regression) would give the best classification of the outcome MCI-stable vs. AD-converters. Genetic search is considered an efficient method for searching large data sets, instead of the computationally demanding alternative of testing all possible combinations (; ). The genetic approach is based around an evolutionary idea where the combined set of biomarkers is “mutated” by diff addition of a random biomarker, removal of a biomarker, random selection of a new set of four biomarkers, and random substitution of a biomarker. Each rule was applied 5 times in each generation, leading to 20 new sets of biomarkers. The classifications of these new sets were then compared with the previous optimal set. Only the best biomarker set survived and was used as the base for next generation of mutations. We did not set limits on the maximum or minimum number of biomarkers in each set.
The genetic algorithm was seeded with an initial set of five biomarkers with the highest Matthew correlation coefficient (see outcome evaluation below). The genetic algorithm ran for 100 generations. At each generation the biomarker set with maximal positive likelihood ratio (see outcome evaluation below) survived. In all cases the logistic regression model was fitted using the second EEG recording, and the classification outcome was measured using the first EEG recording.
Statistics: Elastic Net Logistic Regression
As an alternative to genetic optimization of biomarkers included in the logistic regression, we employed an elastic net logistic regression algorithm () as implemented in the GLMnet package for Matlab () (). This algorithm promises a build-in selection of features that optimally can perform much better than the less stable genetic optimization. The elastic net optimizes the number of biomarkers included in the diagnostic index by minimizing both the L1 and L2 norm of the regression coefficients by minimizing the equation
L(λ1,λ2,β)=|z−Xβ|2+λ1|β|+λ2|β|2
where the first term is similar to the logistic regression, and the second and third are the penalizing terms (the elastic net) (). The parameters λ1 and λ2 determines the influence of either the L1 or L2 norm penalty. We define a new combined parameter
α=λ2λ1+λ2
which we optimized in 5-split cross-validation based on the best classification by training on second-year data, and testing on the 1/5 left-out subject group on first-year EEG (note that subjects which did not have a second-year EEG were not included, and, therefore, serve as our ultimate test group (see Results) (data not shown). We found the best classification with α = 0.8.
Statistics: Classification Outcome Evaluation
To evaluate the outcome of our classification we use five different measures:
• Sensitivity (SE): defined as the (number of correctly classified AD-converter patients)/(number of AD-converter patients).
• Specificity (SP): defined as the (number of correctly classified MCI-stable subjects)/(number of MCI-stable subjects).
• Positive predictive value (PPV): defined as (number of correctly classified AD-converter patients)/(number of patients classified as AD-converters).
• Positive likelihood ratio (PLR): defined as (Sensitivity)/(1-Specificity).
• Matthew correlation coefficient (MCC): explains the correlation between the outcome and the expected outcome ().
A Matthew correlation coefficient higher than 0.20, sensitivity higher than 65%, specificity higher than 65%, positive predictive value higher than 65%, and a positive likelihood ratio higher than 1.6 means that the classification is significantly different from a random classification (Monte Carlo simulation, 5000 iterations, n = 65, note these results depends on the sample size making the threshold levels lower for larger sample sizes, p < 0.05). Perfect classification would give a Matthew correlation coefficient (MCC) of 1, sensitivity of 100%, specificity of 100%, positive predictive value of 100%, and an infinite positive likelihood ratio.
An issue with these outcome measures is that they only tell how well the classification fits the given subgroup of subjects, but not how well the classification generalizes to other subject populations. We counteract this (1) classification was performed on the second EEG recording, whereas the prediction was tested on the first EEG recording, (2) as the ultimate test we evaluated the prediction on subjects not included for classifier training (because not all subjects had a second EEG recording), and (3) we performed a half-split cross-validation. In the half-split cross-validation the sample was divided randomly in half several times (1000 iterations); the classifier was then trained on the first half, and the outcome was evaluated on the second half. We report the median outcome measures over these splits. Cross-validation gives an estimate of the classification performance on an “unknown” sample (). However, cross-validation also suffers from lower n numbers, which means their outcome should be viewed as a conservative estimate of the average outcome.
Statistics: Group Differences and Correlations
We use non-parametric permutation tests based on median (; ) to test for differences between groups. Non-parametric tests are more robust toward non-normal data, but also often have lower power than parametric such as student's t-test. Confidence intervals (95%) were found using non-parametric bias corrected and accelerated bootstrap (n = 5000) ().
Statistics: 2 × 2 Table Independence Tests
To test for dependence of genotype, gender, and patient group we used Barnard's exact test, which is appropriate for low sample statistics compared with Chi-square test, and has better power compared with Fisher's exact test ().
Statistics: Multiple Comparisons
Because we do large-scale mapping of biomarkers, we employ a lenient approach to multiple comparisons correction at the first level of analysis. This means that in the initial mapping of potential difference between the stable MCI and AD-converter groups, we only perform a binomial correction for the number of significant channels in each biomarker (). We do not correct the p-values across different biomarkers. This approach is appropriate since this mapping of potential difference is only used to identify candidate biomarkers for the genetic search algorithm.
Patient Groups—Age and Gender
Initially 86 subjects (Age: 68.7 [66.5:71.3] years, median [95% confidence interval], age at first EEG, 58 males) were diagnosed with mild cognitive impairment (MCI). After 415 ± [393:478] days, 17 patients (9 males) had converted to Alzheimer's disease. After 709 ± [537:779] days (1.9 years) a total of 25 patients (14 males) had converted to AD (Age: 69 ± [67:72] years), 39 subjects (28 males) remained MCI (Age: 67 ± [65:71] years), 9 subjects (6 males) were diagnosed with subjective complaints (Age: 67 ± [46:73] years), and 13 patients (10 males) with other disorders (Age: 70 ± [61:74] years) (including frontal lobe and Vascular dementia). No significant difference was found in age and gender between stable MCI and AD-converters (Gender: Barnard's test, p = 0.16; Age: permutation test, p = 0.49) (Table ). We only focus on the patients diagnosed with AD, and subjects remaining stable MCI. In the following we use the last diagnosis of the subjects for the definition of the MCI-stable and AD-converters groups.
MMSE Results
The MMSE score of the MCI-stable group (28 ± [27:29]) was not significantly different from the score from AD-converter group (27 ± [26:28]) at the intake test (permutation test, p = 0.8). At the follow up approximately 1 year later the stable MCI subjects remained at a stable MMSE score of 28 ± [26:29], whereas the MMSE score of the AD-converter group changed to 24 ± [22:24] (permutation test, p = 0.0044), which is also lower than the stable MCI group's MMSE scores (permutation test, p = 0.0002) (Table ).
APOE Status
We observed a significantly higher frequency of E4 allele vs. no E4 allele in AD-converter vs. stable MCI (Barnard test, p < 0.01). Only 38% of MCI-stable compared to 64% of AD-converter group had more than one E4 allele (Table ).
Table 2. Overview of patient groups.
Single-Biomarker Logistic Regression Model of AD-Converter vs. MCI-Stable
To show the principle of logistic regression modeling on a single biomarker, we chose the beta peak frequency, because this biomarker showed significantly lower values in MCI (MCI: 17.6 ± [16.8:18.2] Hz, n = 39) compared with the AD-converter group (AD: 19.6 ± [18.1:21.0] Hz, n = 25) (p < 0.0005) in the first measurement (Figure ), and also significantly lower values in MCI in the second measurement (MCI: 16.9 ± [16.0:17.8] Hz, n = 17; AD: 19.3 ± [18.6:20.6] Hz, n = 17, p < 0.005) (frequency values are averages across the significant channels) (Figure ).
Figure 3. Integration of multiple biomarkers using logistic regression improves the prediction of Alzheimer's disease at the MCI stage. (A) A significant higher Beta peak frequency is observed in Alzheimer's disease converter group (AD) (red) compared with mild cognitive impairment stable group (MCI) (blue), in both first (left) and second (right) year EEG recording. (permutation test on median, binomial corrected, **p < 0.005, ***p < 0.0005) (B) The logistic model is fitted to the second-year EEG recording. (C) The logistic model is used to predict outcome on the first year EEG recording. Separation plot of AD vs. MCI. (D) Outcome evaluation of beta peak frequency using five measures of classification power (warmer is better). SE, S SP, S PPV, Posit MCC, Matthews Correlation C AUC, area under the receiver operator curve. (E) Outcome evaluation as in (C), but for the “optimal” biomarker set found using genetic search. The first six columns are for classification of the individual biomarkers separately. The last column is the combined classification outcome. We clearly see that the combined outcome is better than the classification using the individual biomarkers. 1, Peak width o 2, range of amplitude values in Beta (13–30 Hz); 3, Bandwidth of subject-specific B 4, Ratio between t 5, alpha relative power (normalized with 1–45 Hz broadband); 6, Amplitude correlations with Cz in Beta (13–30 Hz); (C) Combined logistic classification using the biomarkers 1, 2, 3, 4, 5, and 6. (F) Logistic curve for combined classification based on first-year EEG. (G) Separation plot of MCI vs. AD in first EEG recording using combined classification based on second-year logistic regression coefficients. Note that the recordings used for training in F are different from those used for testing in (G).
We fitted a logistic regression model to the second EEG measurement (n = 17 in both groups, Figure ). The model classified the second measurements with a sensitivity (SE) of 76%, 76% specificity (SP), 76% positive predictive value (PPV), 0.5 Matthew correlation coefficient (MCC), and a positive likelihood ratio (PLR) of 3.3. Next, we used this logistic model to retrospectively classify the first EEG measurement (Figure ). The classification had a SE of 72%, 59% SP, 53% PPV, 0.3 MCC and a PLR of 1.8; thus, as expected, a worse classification power (MCI n = 39, AD n = 25) (Figure ).
Multiple-Biomarker Logistic Regression Model of AD-Converter vs. MCI-Stable
By combining several biomarkers it may be possible to obtain better classification power than the individual biomarkers alone (; ; ). However, it is not trivial which combinations of biomarkers are optimal, because of the high number of possible combinations. Here, we employ a genetic search approach and elastic net penalization to assists us in finding these optimal combinations (see Methods and Materials section).
The best set of biomarkers identified by the genetic search was (six biomarkers): Amplitude correlations with Cz in Beta (13–30 Hz), Bandwidth of subject-specific Beta frequency, Peak width of dominant beta peak, range of amplitude values in Beta (13–30 Hz), Ratio between theta and alpha power, and alpha relative power (normalized with 1–45 Hz broadband). The logistic regression training on this biomarker set using the second EEG data yielded a SE of 100%, 94% SP, 94% PPV, 0.94 MCC, and PLR of 17 (n = 17 in both groups).
The retrospective testing on first-year data using the classifier model trained on the second-year data gave a SE of 92%, 85% SP, 79% PPV, 0.75 MCC, and PLR of 6 (MCI-stable, n = 39; AD-convert, n = 25) (F Table ), which indicates that even at this very early stage differences between AD-converters and MCI-stable can be identified. However, since second-year and first-year data from the same subjects may be strongly correlated we also performed a classification test using only subjects that were not used for training the model (i.e., the subjects without a second EEG recording). We obtained a good classification with a SE of 88%, 82% SP, 64% PPV, 0.64 MCC and a PLR of 4.8 (MCI-stable, n = 22; AD-convert, n = 8), suggesting the diagnostic index can generally be used for these patient groups. Furthermore, we performed a half-split cross-validation (1000 iterations), with a SE of 75%, 63% SP, 52% PPV, 0.37 MCC, and a PLR of 2, an indication of the average outcome. As expected, the classifica however, this is at least partly explained by the lower n number. However, the combined classification is still much better than prediction obtained on the individual biomarkers in the set (Figures , ). The best single biomarker in the biomarker set (based on sensitivity and specificity) was the peak width of the dominant Beta peak, with a SE of 64%, 62% SP, 52% PPV, 0.24 MCC, and a PLR of 1.7 (MCI-stable, n = 22; AD-convert, n = 8) (Table ). The logistic regression fitting coefficients for the co &#x for Amplitude correlations with Cz in Beta, 0.5 for bandwidth of subject specific Beta, 3.4 for Peak width of dominant beta peak, &#x for range of amplitude values in Beta, &#x for ratio between theta and alpha power, and &#x for alpha relative power. This means that the peak width of the dominant beta peak had the greatest influence on the outcome, followed by amplitude correlations with Cz.
Table 3. Overview of classification results [classification based on testing subjects that were not used for training the classifier (MCI-stable, n = 22; AD-convert, n = 8)].
Figure 4. Most biomarkers in the diagnostic index have differences between the MCI-stable (MCI) and AD-converter (AD) groups, and only two have longitudinal changes. For each biomarker, a separation plot is shown for 1st EEG and 2nd EEG. The values are median across channels with significant differences between the MCI-stable (MCI) and AD-converter (AD) groups (Binomial corrected). Topographical plots are of 2nd EEG median value across subjects and channels in 6 Frontal, left/right temporal, Central, Parietal, and Occipital. Asterisk indicates significant differences (permutation test on median, binomial corrected, *p < 0.05, **p < 0.005).
Taken together, our results show that it is possible to obtain a substantial synergistic effect from the integration o however, they also show that it is not trivial to identify which combination of biomarkers is most optimal. The major issue with our genetic search is that from run to run we do not obtain the same solution, because the algorithm finds local maxima. We, therefore, employed an elastic net penalized logistic regression algorithm. This algorithm uses a penalization of the weights to optimize the set of biomarkers used for classification. The classification outcome from this algorithm is worse than genetic search optimized logistic regression, with a SE of 75%, 86% SP, 67% PPV, 0.59 MCC, and a PLR of 5.5 (MCI-stable, n = 22; AD-convert, n = 8) (Table ) based on training on the second-year EEG and testing on the first-year recording of subjects (the test subjects were not used for training). The elastic net logistic regression combined 12 biomarkers (non-zero weights), the amplitude correlations from Cz in Alpha (8–13 Hz) and Beta (13–30 Hz), the range of the generalized multifractal hurst exponent of the Delta (1–3 Hz) amplitude envelope, the Beta frequency, the power ratio between Gamma (30–45 Hz) and Delta (1–4 Hz), Alpha 1 (Individual Alpha frequency-4: Individual Alpha frequency-2) and Alpha (8–13), Alpha 1 and Beta (13–30 Hz), the spectral edge of the individualized beta-frequency range, the peak width of the beta peak, the second beta peak frequency, the stability of the Delta (1–3 Hz) frequency measured in windows of 5 s, and the Hjorth mobility parameter. The outcome evaluation still shows room for improvement, e.g., by including biomarkers from other modalities.
Discussion
We addressed the challenge of predicting whether an MCI subject would convert to AD within 2 years. To this end, we explored the added value of integrating multiple EEG biomarkers into a diagnostic index using logistic regression in combination with either a genetic search or elastic-net penalization for biomarker selection. From an initial cohort of 86 subjects with mild cognitive impairment, 25 converted to Alzheimer's disease within 2 years. We showed how data mining of 177 EEG biomarkers could be used to identify a set of biomarkers that form a diagnostic index. The analysis was performed using the Neurophysiological Biomarker Toolbox (NBT, ) (), which is specifically developed to support data mining and integration of large sets of biomarkers. We found that particularly biomarkers sensitive to changes in the beta frequency (13–30 Hz) band were optimal for classifying the very early EEG recordings of yet to be diagnosed AD patients.
Classification Based Diagnostics
Previous studies have shown promise in using machine-learning algorithms to classify between MCI and AD based on EEG recordings (; ; ; ; ; ; ). A sensitivity of 89% and specificity of 95% were, e.g., found using the so-called IFAST model (; ). However, these studies were based on training and testing on the same data, which makes it more difficult to judge the performance. Uniquely to the present study, we performed classification training on the second EEG recording, and retrospectively used this to perform prediction based on the first EEG recording from subjects not used for the training. We note, however, that the drawback of the present procedure is the low number of patients in the smallest patient group (i.e., the eight patients converting to AD) produced a fairly high error margin to the classification estimates (12.5%).
Oscillations are Involved in Cognition
Empirical and theoretical evidence suggest that oscillations provide important systems-level mechanisms for normal brain function (; ; ; ; , ; ). For example, oscillations are involved in memory encoding (; ), and are thought to provide a timing mechanism for spike-time dependent plasticity (). It, therefore, seem plausible that if oscillations are abnormal in disorders such as MCI and AD, then cognition is also affected. Apart from relative Alpha power and the theta/alpha power ratio, which may reflect early changes toward the well-known slowing of the EEG in AD (; ), our optimal set of biomarkers is derived from the Beta frequency band (13–30 Hz).
Beta-band changes have previously been observed in Alzheimer's disease, e.g., by a more anterior distribution (). The larger width of the beta peak and bandwidth could potentially be linked with a less stable beta frequency, and, therefore, also a less efficient working memory (). Beta oscillations are believed to maintain the current sensorimotor and cognitive state (). Activity in the beta-frequency range has also traditionally been linked with motor function. Interestingly, it has been found that motor performance is impaired in early-stage Alzheimer's disease but not in mild cognitive impairment (; ), which is a potential explanation of the prominent role of beta-frequency changes in our data. Motor function, e.g., gait control, is a higher cognitive function requiring integration of several cognitive functions, as attention, planning (; ), albeit unrelated to performance in memory tests (). Hyperexcitability of the motor cortex has also been observed in AD (), which our finding of higher beta frequency also suggests.
EEG Biomarkers as Potential Indicators of Inflammation
The standard hypothesis of Alzheimer's disease is the amyloid cascade hypothesis stating that the cause of Alzheimer's should be found in the build up of amyloid and tangles (; ). It has been hypothesized that Alzheimer's disease is initiated by a micro injury, presumable a vascular event, in the brain with subsequent activation of inflammatory responses that further leads to initiation of the amyloid deposition cycle (; ).
The theta/(lower alpha) power ratio has previously been associated with vascular damage in AD (), and the delta (2–4 Hz) power has been associated with inflammation (). EEG power and frequency in general has also been correlated with cerebral perfusion (), which is known to be reduced in Alzheimer's disease (; ; ). If we could detect early-stage changes using EEG, we would have a powerful tool that could detect Alzheimer's disease at a point where a possible therapy would be most efficient. Mouse models, e.g., show that Aβ-42 modifying therapy has limited effect after neurodegeneration has begun (; ). Thus, meaning that diagnosing a patient based on neurodegeneration and cognitive decline may already be too late for a good treatment outcome because the brain damage has already occurred.
It has also been shown that the build-up of Aβ 42 influences synaptic transmission, and thus, potentially also give rise to further effects in the EEG (; ). Further hippocampal injections of amyloid β in rats have been shown to induce impaired memory performance combined with reduced hippocampal theta oscillations and less activity in GABAergic neurons (GABA, gamma-aminobutyric acid) (). A recent suggestion for a potential improvement of Alzheimer's disease symptoms is transcranial direct current stimulation (tDCS) (). This method increased theta and alpha oscillations together with improved working memory performance (). Interestingly, it has been suggested these effects may be caused by altered GABA concentration within the stimulated cortex, and potentially by an adjustment of the excitatory/inhibitory balance, which is disturbed in Alzheimer's disease (; ; ). This balance may be directly linked to EEG biomarkers that have been shown sensitive to Alzheimer's disease (; , ). It thus seems that EEG biomarkers may be sensitive to underlying pathophysiology of AD.
We here showed that exploratory data mining and integration of multiple biomarkers might yield many exciting results on the large databases of neuroscience data build up over the years. These studies may identify hidden structures (see schematic Figure ) and be beneficial for both pre-clinical and clinical research. With recent developments in automatic cleaning of EEG this analysis may potentially be performed immediately after the recording (; ). This together with the non-invasive character of EEG could make a diagnostic index using EEG biomarkers a powerful tool to support the early-stage clinical assessment. EEG biomarkers, apart from being non-invasive and relative inexpensive, have the advantage of monitoring brain activity in real time, and thus potentially able to identify tiny changes in ongoing cognition. However, we believe the best diagnostic/prognostic performance is achieved if EEG biomarkers are combined with information from other modalities. Future studies should specifically study how the synergistic information of integrative biomarkers can be improved further by the incorporation of different classes of biomarkers, which could range from cognitive markers (), functional connectivity markers (, ), coherence, synchronization, and topographical location markers (; ; ) to questionnaire data providing quantitative data on the mental state of the patients during the resting-state EEG recording (). Improvement in algorithms used for pre-selecting biomarkers could, e.g., be based on measures of interrelatedness between biomarkers or taking scalp topographies into account as opposed to the averaged channel biomarker values used here. We believe the Neurophysiological Biomarker toolbox provides a promising framework for these studies. This could give rise to a better integrative understanding of biomarkers involved with Alzheimer's disease and brain disorders in general (; ; ).
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This work was supported by Netherlands Organization for Scientific Research (NWO), with a Toptalent grant (Grant nr. 021.002.080) to Simon-Shlomo Poil. The authors would like to acknowledge Emi Saliasi for help with data collection. The authors would like to thank C. J. Stam for sharing the clinical data.
References
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement. 7, 270&#x. doi: 10.1016/j.jalz.
Antila, K., Lötjönen, J., Thurfjell, L., Laine, J., Massimini, M., Rueckert, D., et al. (2013). The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease. Interface Focus 3. doi: 10.1098/rsfs.
Axmacher, N., Mormann, F., Fernández, G., Elger, C. E., and Fell, J. (2006). Memory formation by neuronal synchronization. Brain Res. Rev. 52, 170&#x. doi: 10.1016/j.brainresrev.
Babiloni, C., Binetti, G., Cassetta, E., Forno, G. D., Percio, C. D., Ferreri, F., et al. (2006). Sources of cortical rhythms change as a function of cognitive impairment in pathological aging: a multicenter study. Clin. Neurophysiol. 117, 252&#x. doi: 10.1016/j.clinph.
Babiloni, C., Frisoni, G. B., Del Percio, C., Zanetti, O., Bonomini, C., Cassetta, E., et al. (2009). Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer's disease. Clin. Neurophysiol. 120, 709&#x. doi: 10.1016/j.clinph.
Babiloni, C., Frisoni, G. B., Vecchio, F., Lizio, R., Pievani, M., Cristina, G., et al. (2011). Stability of clinical condition in mild cognitive impairment is related to cortical sources of alpha rhythms: An electroencephalographic study. Hum. Brain Mapp. 32, 1916&#x. doi: 10.1002/hbm.21157
Baldi, P., Brunak, S., Chauvin, Y., Andersen, C. A. F., and Nielsen, H. (2000). Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics rev. 16, 412&#x. doi: 10.1093/bioinformatics/16.5.412
Barnard, G. A. (1947). Significance tests for 2X2 tables. Biometrika 34, 123&#x.
Bennys, K., Rondouin, G., Vergnes, C., and Touchon, J. (2001). Diagnostic value of quantitative EEG in Alzheimer's disease. Neurophysiol. Clin. Neurophysiol. 31, 153&#x. doi: 10.-54-4
Blennow, K., de Leon, M. J., and Zetterberg, H. (2006). Alzheimer's disease. Lancet 368, 387&#x. doi: 10.-13-7
Box, G. E., and Andersen, S. L. (1955). Permutation theory in the derivation of robust criteria and the study of departures from assumption. J. R. Stat. Soc. Ser. B Methodol. 17, 1–34.
Buscema, M., Rossini, P., Babiloni, C., and Grossi, E. (2007). The IFAST model, a novel parallel nonlinear EEG analysis technique, distinguishes mild cognitive impairment and Alzheimer's disease patients with high degree of accuracy. Artif. Intell. Med. 40, 127&#x. doi: 10.1016/j.artmed.
Buzsáki, G., and Draguhn, A. (2004). Neuronal oscillations in cortical networks. Science 304, 1926&#x. doi: 10.1126/science.1099745
Cardoso, J. F., and Souloumiac, A. (1993). Blind beamforming for non-Gaussian signals. IEEE Proc. F 140, 362&#x. doi: 10.1049/ip-f-2.
De la Torre, J. C. (1999). Critical threshold cerebral hypoperfusion causes Alzheimer's disease. Acta Neuropathol. 98, 1–8. doi: 10.051044
De la Torre, J. C. (2004). Is Alzheimer's disease a neurodegenerative or a vascular disorder. Data, dogma, and dialectics. Lancet Neurol. 3, 184&#x. doi: 10.-83-0
Di Lazzaro, V., Oliviero, A., Pilato, F., Saturno, E., Dileone, M., Marra, C., et al. (2004). Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr. 75, 555&#x. doi: 10.1136/jnnp.
Diaz, B. A., van der Sluis, S., Moens, S., Benjamins, J. S., Migliorati, F., Stoffers, D., et al. (2013). The Amsterdam Resting-State Questionnaire reveals multiple phenotypes of resting-state cognition. Front. Hum. Neurosci. 7:446. doi: 10.3389/fnhum.
DiCiccio, T. J., and Efron, B. (1996). Bootstrap confidence intervals. Stat. Sci. 11, 189&#x.
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurol. 6, 734&#x. doi: 10.-78-3
Engel, A. K., and Fries, P. (2010). Beta-band oscillations—signalling the status quo. Curr. Opin. Neurobiol. 20, 156&#x. doi: 10.1016/j.conb.
Engel, A. K., and Singer, W. (2001). Temporal binding and the neural correlates of sensory awareness. Trends Cogn. Sci. 5, 16–25.
Ernst, M. D. (2004). Permutation methods: a basis for exact inference. Stat. Sci. 19, 676&#x. doi: 10.
Flicker, C., Ferris, S. H., and Reisberg, B. (1991). Mild cognitive impairment in the elderly. Neurology 41, 1006&#x. doi: 10.1212/WNL.41.7.1006
Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189&#x. doi: 10.56(75)90026-6
Friedman, J., Hastie, T., and Tibshirani, R. (2010). Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1–22.
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., et al. (2006). Mild cognitive impairment. Lancet 367, 1262&#x. doi: 10.-42-5
Goncharova, I. I., and Barlow, J. S. (1990). Changes in EEG mean frequency and spectral purity during spontaneous alpha blocking. Electroencephalogr. Clin. Neurophysiol. 76, 197&#x. doi: 10.94(90)90015-C
Hansen, N. (2012). Action mechanisms of transcranial direct current stimulation in Alzheimer's disease and memory loss. Front. Psychiatry 3:48. doi: 10.3389/fpsyt.
Hardstone, R., Poil, S.-S., Schiavone, G., Jansen, R., Nikulin, V. V., Mansvelder, H. D., et al. (2012). Detrended fluctuation analysis: a scale-free view on neuronal oscillations. Front. Physiol. 3:450. doi: 10.3389/fphys.
Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353&#x. doi: 10.1126/science.1072994
Hausdorff, J. M., Yogev, G., Springer, S., Simon, E. S., and Giladi, N. (2005). Walking is more like catching than tapping: gait in the elderly as a complex cognitive task. Exp. Brain Res. 164, 541&#x. doi: 10.-005-2280-3
Herrup, K. (2010). Reimagining Alzheimer's disease—an age-based hypothesis. J. Neurosci. 30, 16755&#x. doi: 10.1523/JNEUROSCI.0
Hjorth, B. (1970). EEG analysis based on time domain properties. Electroencephalogr. Clin. Neurophysiol. 29, 306&#x. doi: 10.94(70)90143-4
Huang, C., Wahlund, L. O., Dierks, T., Julin, P., Winblad, B., and Jelic, V. (2000). Discrimination of Alzheimer's disease and mild cognitive impairment by equivalent EEG sources: a cross-sectional and longitudinal study. Clin. Neurophysiol. 111, 1961&#x. doi: 10.-54-5
Huang, L., and Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204&#x. doi: 10.1016/j.cell.
Hughes, C. P., Berg, L., Danziger, W. L., Coben, L. A., and Martin, R. L. (1982). A new clinical scale for the staging of dementia. Br. J. Psychiatry 140, 566&#x. doi: 10.1192/bjp.140.6.566
Ihlen, E. A. F. (2012). Introduction to multifractal detrended fluctuation analysis in matlab. Front. Physiol. 3:141. doi: 10.3389/fphys.
Jelic, V., Johansson, S. E., Almkvist, O., Shigeta, M., Julin, P., Nordberg, A., et al. (2000). Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease. Neurobiol. Aging 21, 533&#x. doi: 10.-53-6
Jelic, V., Shigeta, M., Julin, P., Almkvist, O., Winblad, B., and Wahlund, L. O. (1996). Quantitative electroencephalography power and coherence in Alzheimer's disease and mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 7, 314&#x. doi: 10.97
Jensen, O., Gelfand, J., Kounios, J., and Lisman, J. E. (2002). Oscillations in the alpha band (9–12 Hz) increase with memory load during retention in a short-term memory task. Cereb. Cortex 12, 877&#x. doi: 10.1093/cercor/12.8.877
Kantelhardt, J. W., Zschiegner, S. A., Koscielny-Bunde, E., Havlin, S., Bunde, A., and Stanley, H. E. (2002). Multifractal detrended fluctuation analysis of nonstationary time series. Phys. Stat. Mech. Appl. 316, 87&#x. doi: 10.-83-3
Klimesch, W. (1999). EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis. Brain Res. Rev. 29, 169&#x. doi: 10.-56-3
Klimesch, W., Sauseng, P., and Hanslmayr, S. (2007). EEG alpha oscillations: the inhibition–timing hypothesis. Brain Res. Rev. 53, 63–88. doi: 10.1016/j.brainresrev.
Kogure, D., Matsuda, H., Ohnishi, T., Asada, T., Uno, M., Kunihiro, T., et al. (2000). Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J. Nucl. Med. 41, 1155.
Kopell, N., Whittington, M. A., and Kramer, M. A. (2011). Neuronal assembly dynamics in the beta1 frequency range permits short-term memory. Proc. Natl. Acad. Sci. U.S.A. 108, 3779&#x. doi: 10.1073/pnas.
Koza, J., and Poli, R. (2005). “Genetic programming,” in Search Methodologies, (Heidelberg: Springer), 127&#x.
Kwak, Y. T. (2006). Quantitative EEG findings in different stages of Alzheimer's disease. J. Clin. Neurophysiol. 23, 457. doi: 10.1097/01.wnp..47663.63
Lehmann, C., Koenig, T., Jelic, V., Prichep, L., John, R. E., Wahlund, L. O., et al. (2007). Application and comparison of classification algorithms for recognition of Alzheimer's disease in electrical brain activity (EEG). J. Neurosci. Methods 161, 342&#x. doi: 10.1016/j.jneumeth.
Linkenkaer-Hansen, K., Nikouline, V. V., Palva, J. M., and Ilmoniemi, R. J. (2001). Long-range temporal correlations and scaling behavior in human brain oscillations. J. Neurosci. 21, 1370.
Lisman, J. (2010). Working memory: the importance of theta and gamma oscillations. Curr. Biol. 20, R490&#x0. doi: 10.1016/j.cub.
Luckhaus, C., Grass-Kapanke, B., Blaeser, I., Ihl, R., Supprian, T., Winterer, G., et al. (2008). Quantitative EEG in progressing vs stable mild cognitive impairment (MCI): results of a 1-year follow-up study. Int. J. Geriatr. Psychiatry 23, 1148&#x. doi: 10.1002/gps.2042
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease. Neurology 34, 939&#x. doi: 10.1212/WNL.34.7.939
Mognon, A., Jovicich, J., Bruzzone, L., and Buiatti, M. (2011). ADJUST: an automatic EEG artifact detector based on the joint use of spatial and temporal features. Psychophysiology 48, 229&#x. doi: 10.1111/j.10.01061.x
Montez, T., Poil, S.-S., Jones, B. F., Manshanden, I., Verbunt, J., Van Dijk, B. W., et al. (2009). Altered temporal correlations in parietal alpha and prefrontal theta oscillations in early-stage Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 106, 1614. doi: 10.1073/pnas.
Moretti, D. V., Frisoni, G. B., Fracassi, C., Pievani, M., Geroldi, C., Binetti, G., et al. (2011). MCI patients' EEGs show group differences between those who progress and those who do not progress to AD. Neurobiol. Aging 32, 563&#x. doi: 10.1016/j.neurobiolaging.
Moretti, D. V., Miniussi, C., Frisoni, G. B., Geroldi, C., Zanetti, O., Binetti, G., et al. (2007a) Hippocampal atrophy and EEG markers in subjects with mild cognitive impairment. Clin. Neurophysiol. 118, 2716&#x. doi: 10.1016/j.clinph.
Moretti, D. V., Miniussi, C., Frisoni, G., Zanetti, O., Binetti, G., Geroldi, C., et al. (2007b) Vascular damage and EEG markers in subjects with mild cognitive impairment. Clin. Neurophysiol. 118, 1866&#x. doi: 10.1016/j.clinph.
Moretti, D. V., Pievani, M., Fracassi, C., Geroldi, C., Calabria, M., De Carli, C. S., et al. (2008). Brain vascular damage of cholinergic pathways and EEG markers in mild cognitive impairment. J. Alzheimers Dis. 15, 357&#x.
Murray, I. V. J., Proza, J. F., Sohrabji, F., and Lawler, J. M. (2011). Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp. Biol. Med. 236, 772&#x. doi: 10.1258/ebm.
Nolan, H., Whelan, R., and Reilly, R. B. (2010). FASTER: fully automated statistical thresholding for EEG artifact rejection. J. Neurosci. Methods 192, 152&#x. doi: 10.1016/j.jneumeth.
O'Gorman, R. L., Poil, S.-S., Brandeis, D., Klaver, P., Bollmann, S., Ghisleni, C., et al. (2013). Coupling between resting cerebral perfusion and EEG. Brain Topogr. 26, 442&#x. doi: 10.-012-0265-7
Palop, J. J., and Mucke, L. (2009). Epilepsy and cognitive impairments in alzheimer disease. Arch. Neurol. 66, 435&#x. doi: 10.1001/archneurol.2009.15
Palva, S., and Palva, J. M. (2007). New vistas for Alpha-frequency band oscillations. Trends Neurosci. 30, 150&#x. doi: 10.1016/j.tins.
Palva, S., and Palva, J. M. (2012). Discovering oscillatory interaction networks with M/EEG: challenges and breakthroughs. Trends Cogn. Sci. Available online at:
[Accessed November 3, 2012].
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., and Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303. doi: 10.1001/archneur.56.3.303
Pettersson, A. F., Olsson, E., and Wahlund, L. O. (2005). Motor function in subjects with mild cognitive impairment and early Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 19, 299&#x. doi: 10.55
Poil, S.-S., Hardstone, R., Mansvelder, H. D., and Linkenkaer-Hansen, K. (2012). Critical-state dynamics of avalanches and oscillations jointly emerge from balanced excitation/inhibition in neuronal networks. J. Neurosci. 32, 9817&#x. doi: 10.1523/JNEUROSCI.2
Poil, S.-S., Jansen, R., van Aerde, K., Timmerman, J., Brussaard, A. B., Mansvelder, H. D., et al. (2011). Fast network oscillations in vitro exhibit a slow decay of temporal auto-correlations. Eur. J. Neurosci. 34, 394&#x. doi: 10.1111/j.11.07748.x
Poil, S.-S., van Ooyen, A., and Linkenkaer-Hansen, K. (2008). Avalanche dynamics of human brain oscillations: relation to critical branching processes and temporal correlations. Hum. Brain Mapp. 29, 770&#x. doi: 10.1002/hbm.20590
Prichep, L. S. (2007). Quantitative EEG and electromagnetic brain imaging in aging and in the evolution of dementia. Ann. N.Y. Acad. Sci. &#x. doi: 10.1196/annals.
Prichep, L. S., John, E. R., Ferris, S. H., Rausch, L., Fang, Z., Cancro, R., et al. (2006). Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imaging. Neurobiol. Aging 27, 471&#x. doi: 10.1016/j.neurobiolaging.
Prins, N. D., Visser, P. J., and Scheltens, P. (2010). Can novel therapeutics halt the amyloid cascade. Alzheimers Res. Ther. 2. Available online at:
(Accessed June 19, 2012).
Raghavachari, S., Kahana, M. J., Rizzuto, D. S., Caplan, J. B., Kirschen, M. P., Bourgeois, B., et al. (2001). Gating of human theta oscillations by a working memory task. J. Neurosci. 21, 3175&#x.
Rombouts, S. A. R., Barkhof, F., Goekoop, R., Stam, C. J., and Scheltens, P. (2005). Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum. Brain Mapp. 26, 231&#x. doi: 10.1002/hbm.20160
Rossini, P., Buscema, M., Capriotti, M., Grossi, E., Rodriguez, G., Del Percio, C., et al. (2008). Is it possible to automatically distinguish resting EEG data of normal elderly vs. mild cognitive impairment subjects with HIGH degree of accuracy? Clin. Neurophysiol. 119, 1534&#x. doi: 10.1016/j.clinph.
Rossini, P. M., Rossi, S., Babiloni, C., and Polich, J. (2007). Clinical neurophysiology of aging brain: From normal aging to neurodegeneration. Prog. Neurobiol. 83, 375&#x. doi: 10.1016/j.pneurobio.
Rossini, P., Del Percio, C., Pasqualetti, P., Cassetta, E., Binetti, G., Dal Forno, G., et al. (2006). Conversion from mild cognitive impairment to Alzheimer's disease is predicted